These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
385 related items for PubMed ID: 21801058
21. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease. Caivano D, Rishniw M, Birettoni F, Patata V, Giorgi ME, Porciello F. J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124 [Abstract] [Full Text] [Related]
22. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. J Am Vet Med Assoc; 2008 May 15; 232(10):1496-503. PubMed ID: 18479239 [Abstract] [Full Text] [Related]
25. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. J Small Anim Pract; 2010 Feb 15; 51(2):84-96. PubMed ID: 20070494 [Abstract] [Full Text] [Related]
26. Mitral Regurgitation Severity and Left Ventricular Systolic Dimension Predict Survival in Young Cavalier King Charles Spaniels. Reimann MJ, Møller JE, Häggström J, Martinussen T, Zatrazemi SSC, Svanholm L, Nielsen LBM, Pedersen HD, Olsen LH. J Vet Intern Med; 2017 Jul 15; 31(4):1008-1016. PubMed ID: 28573754 [Abstract] [Full Text] [Related]
27. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs. Lee CM, Jeong DM, Kang MH, Kim SG, Han JI, Park HM. Am J Vet Res; 2017 Apr 15; 78(4):440-446. PubMed ID: 28345991 [Abstract] [Full Text] [Related]
28. Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs. Fonfara S, Loureiro J, Swift S, James R, Cripps P, Dukes-McEwan J. Vet J; 2010 Jun 15; 184(3):334-9. PubMed ID: 19703781 [Abstract] [Full Text] [Related]
34. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K. J Vet Intern Med; 2013 Jun 15; 27(6):1452-62. PubMed ID: 24128373 [Abstract] [Full Text] [Related]
37. Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans. Aupperle H, Disatian S. J Vet Cardiol; 2012 Mar 15; 14(1):59-71. PubMed ID: 22364722 [Abstract] [Full Text] [Related]
38. Flow-mediated vasodilation measurements in Cavalier King Charles Spaniels with increasing severity of myxomatous mitral valve disease. Moesgaard SG, Klostergaard C, Zois NE, Teerlink T, Molin M, Falk T, Rasmussen CE, Luis Fuentes V, Jones ID, Olsen LH. J Vet Intern Med; 2012 Mar 15; 26(1):61-8. PubMed ID: 22151409 [Abstract] [Full Text] [Related]
39. Assessment of global and regional left ventricular volume and shape by real-time 3-dimensional echocardiography in dogs with myxomatous mitral valve disease. Ljungvall I, Höglund K, Carnabuci C, Tidholm A, Häggström J. J Vet Intern Med; 2011 Mar 15; 25(5):1036-43. PubMed ID: 21848946 [Abstract] [Full Text] [Related]